Sema4A 抑制 IFN-β 在 EAE 中的治疗效果。
Sema4A inhibits the therapeutic effect of IFN-β in EAE.
机构信息
Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
出版信息
J Neuroimmunol. 2014 Mar 15;268(1-2):43-9. doi: 10.1016/j.jneuroim.2013.12.014. Epub 2014 Jan 7.
Approximately one-third of patients with multiple sclerosis (MS) respond poorly to interferon-beta (IFN-β) therapy. Serum Sema4A is increased in MS patients, and those who have high Sema4A do not respond to IFN-β therapy. In this study, we investigated whether recombinant Sema4A abrogates the efficacy of IFN-β in mice with experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Administration of Sema4A concurrently with IFN-β diminished the efficacy of IFN-β in EAE. These effects of Sema4A were attributed to promote Th1 and Th17 differentiation and to increase adhesive activation of T cells to endothelial cells, even in the presence of IFN-β.
大约三分之一的多发性硬化症 (MS) 患者对干扰素-β (IFN-β) 治疗反应不佳。MS 患者的血清 Sema4A 增加，而 Sema4A 水平高的患者对 IFN-β 治疗无反应。在这项研究中，我们研究了重组 Sema4A 是否会破坏实验性自身免疫性脑脊髓炎 (EAE) 小鼠（MS 的动物模型）中 IFN-β 的疗效。Sema4A 与 IFN-β 同时给药会降低 IFN-β 在 EAE 中的疗效。Sema4A 的这些作用归因于促进 Th1 和 Th17 分化，并增加 T 细胞与内皮细胞的黏附激活，即使存在 IFN-β 也是如此。
Zotero 插件